Search

Your search keyword '"Deneer, Vera H.M."' showing total 138 results
Start Over Author "Deneer, Vera H.M."
138 results on '"Deneer, Vera H.M."'

4. Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial

Author

Willemsen, Laura M., Janssen, Paul W.A., Peper, Joyce, Soliman-Hamad, Mohamed A., van Straten, Albert H.M., Klein, Patrick, Hackeng, Chris M., Sonker, Uday, Bekker, Margreet W.A., von Birgelen, Clemens, Brouwer, Marc A., van der Harst, Pim, Vlot, Eline A., Deneer, Vera H.M., Chan Pin Yin, Dean R.P.P., Gimbel, Marieke E., Beukema, Kasper F., Daeter, Edgar J., Kelder, Johannes C., Tijssen, Jan G.P., Rensing, Benno J.W.M., van Es, Hendrik W., Swaans, Martin J., and ten Berg, Jurrien M.

Published
2020
Full Text
View/download PDF

5. Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

Author

van der Wouden, Cathelijne H., Böhringer, Stefan, Cecchin, Erika, Cheung, Ka-Chun, Dávila-Fajardo, Cristina Lucía, Deneer, Vera H.M., Dolžan, Vita, Ingelman-Sundberg, Magnus, Jönsson, Siv, Karlsson, Mats O., Kriek, Marjolein, Mitropoulou, Christina, Patrinos, George P., Pirmohamed, Munir, Rial-Sebbag, Emmanuelle, Samwald, Matthias, Schwab, Matthias, Steinberger, Daniela, Stingl, Julia, Sunder-Plassmann, Gere, Toffoli, Giuseppe, Turner, Richard M., van Rhenen, Mandy H., van Zwet, Erik, Swen, Jesse J., and Guchelaar, Henk-Jan

Published
2020
Full Text
View/download PDF

6. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate

Author

Apotheek Klinische Farmacie, Nijenhuis, Marga, Soree, Bianca, Jama, Wafa O.M., de Boer-Veger, Nienke J., Buunk, Anne Marie, Guchelaar, Henk Jan, Houwink, Elisa J.F., Rongen, Gerard A., van Schaik, Ron H.N., Swen, Jesse J., Touw, Daan, van der Weide, Jan, van Westrhenen, Roos, Deneer, Vera H.M., Risselada, Arne, Apotheek Klinische Farmacie, Nijenhuis, Marga, Soree, Bianca, Jama, Wafa O.M., de Boer-Veger, Nienke J., Buunk, Anne Marie, Guchelaar, Henk Jan, Houwink, Elisa J.F., Rongen, Gerard A., van Schaik, Ron H.N., Swen, Jesse J., Touw, Daan, van der Weide, Jan, van Westrhenen, Roos, Deneer, Vera H.M., and Risselada, Arne

Published
2023

7. Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan

Author

Apotheek Klinische Farmacie, Hulshof, Emma C., Deenen, Maarten J., Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Risselada, Arne, Rongen, Gerard A.P.J.M., van Schaik, Ron H.N., Touw, Daan J., van der Weide, Jan, van Westrhenen, Roos, Deneer, Vera H.M., Guchelaar, Henk Jan, Swen, Jesse J., Apotheek Klinische Farmacie, Hulshof, Emma C., Deenen, Maarten J., Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Risselada, Arne, Rongen, Gerard A.P.J.M., van Schaik, Ron H.N., Touw, Daan J., van der Weide, Jan, van Westrhenen, Roos, Deneer, Vera H.M., Guchelaar, Henk Jan, and Swen, Jesse J.

Published
2023

8. Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients

Author

Apotheek Opleiding, Onderzoek, Brain, Apotheek, Apotheek Klinische Farmacie, den Uil, Manon G., Hut, Hannelotte W., Wagelaar, Kay R., Abdullah-Koolmees, Heshu, Cahn, Wiepke, Wilting, Ingeborg, Deneer, Vera H.M., Apotheek Opleiding, Onderzoek, Brain, Apotheek, Apotheek Klinische Farmacie, den Uil, Manon G., Hut, Hannelotte W., Wagelaar, Kay R., Abdullah-Koolmees, Heshu, Cahn, Wiepke, Wilting, Ingeborg, and Deneer, Vera H.M.

Published
2023

11. Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial

Author

Tavenier, Anne H., Claassens, Daniel M.F., Hermanides, Renicus S., Vos, Gerrit J.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., van 't Hof, Arnoud W.J., ten Berg, Jurriën M., Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
STEMI, clopidogrel, Radiology Nuclear Medicine and imaging, glycoprotein IIb/IIIa inhibitors, primary percutaneous coronary intervention, Cardiology and Cardiovascular Medicine, ticagrelor
Abstract

Background: Glycoprotein IIb/IIIa inhibitors (GPI) are still used in patients with ST-segment elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI), although discussion about its clinical benefit is ongoing. Methods: GPI use was analyzed in this subanalysis of the POPular Genetics trial, which randomized STEMI patients to CYP2C19 genotype-guided treatment (clopidogrel or ticagrelor) or standard treatment with ticagrelor/prasugrel. The composite thrombotic endpoint consisted of cardiovascular death, myocardial infarction (MI), definite stent thrombosis, and stroke at 30 days. The combined bleeding endpoint consisted of Platelet Inhibition and Patient Outcomes (PLATO) major and minor bleeding at 30 days. Univariable and multivariable analyses in addition to a propensity score-matched (PSM) analysis were conducted. Results: In total, 2378 patients, of whom 1033 received GPI and 1345 did not, were included. In multivariable analysis, GPI administration was associated with fewer thrombotic events (hazard ratio [HR] 0.22, 95% confidence interval [CI] 0.09–0.55) and MIs (HR 0.24, 95% CI 0.08–0.73). Furthermore, GPI administration was associated with an increase in bleedings (HR 2.02, 95% CI 1.27–3.19), driven by minor bleedings (HR 2.32, 95% CI 1.43–3.76), without a significant difference in major bleedings (HR 0.69, 95% CI 0.19–2.57). In the PSM analysis, no significant association was found. Conclusion: In STEMI patients undergoing primary PCI, GPI administration was associated with a reduction in thrombotic events at a cost of an increase in (mostly minor) bleedings in multivariable analysis, while propensity score analysis did not show significant associations.

Published
2022

12. Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Tavenier, Anne H., Claassens, Daniel M.F., Hermanides, Renicus S., Vos, Gerrit J.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., van 't Hof, Arnoud W.J., ten Berg, Jurriën M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Tavenier, Anne H., Claassens, Daniel M.F., Hermanides, Renicus S., Vos, Gerrit J.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., van 't Hof, Arnoud W.J., and ten Berg, Jurriën M.

Published
2022

13. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Brouwer, Jurriaan M.J.L., Nijenhuis, Marga, Soree, Bianca, Guchelaar, Henk Jan, Swen, Jesse J., van Schaik, Ron H.N., Weide, Jan van der, Rongen, Gerard A.P.J.M., Buunk, Anne Marie, de Boer-Veger, Nienke J., Houwink, Elisa J.F., van Westrhenen, Roos, Wilffert, Bob, Deneer, Vera H.M., Mulder, Hans, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Brouwer, Jurriaan M.J.L., Nijenhuis, Marga, Soree, Bianca, Guchelaar, Henk Jan, Swen, Jesse J., van Schaik, Ron H.N., Weide, Jan van der, Rongen, Gerard A.P.J.M., Buunk, Anne Marie, de Boer-Veger, Nienke J., Houwink, Elisa J.F., van Westrhenen, Roos, Wilffert, Bob, Deneer, Vera H.M., and Mulder, Hans

Published
2022

14. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Matic, Maja, Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A.P.J.M., Weide, Jan van der, Wilffert, Bob, Swen, Jesse J., Guchelaar, Henk Jan, Deneer, Vera H.M., van Schaik, Ron H.N., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Matic, Maja, Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A.P.J.M., Weide, Jan van der, Wilffert, Bob, Swen, Jesse J., Guchelaar, Henk Jan, Deneer, Vera H.M., and van Schaik, Ron H.N.

Published
2022

15. Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Claassens, Daniel M.F., van Dorst, Pim W.M., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Postma, Maarten J., Deneer, Vera H.M., ten Berg, Jurriën M., Boersma, Cornelis, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Claassens, Daniel M.F., van Dorst, Pim W.M., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Postma, Maarten J., Deneer, Vera H.M., ten Berg, Jurriën M., and Boersma, Cornelis

Published
2022

16. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Matic, Maja, Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A.P.J.M., Weide, Jan van der, Wilffert, Bob, Swen, Jesse J., Guchelaar, Henk Jan, Deneer, Vera H.M., van Schaik, Ron H.N., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Matic, Maja, Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A.P.J.M., Weide, Jan van der, Wilffert, Bob, Swen, Jesse J., Guchelaar, Henk Jan, Deneer, Vera H.M., and van Schaik, Ron H.N.

Published
2022

17. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs

Author

Brouwer, Jurriaan M.J.L., Nijenhuis, Marga, Soree, Bianca, Guchelaar, Henk Jan, Swen, Jesse J., van Schaik, Ron H.N., Weide, Jan van der, Rongen, Gerard A.P.J.M., Buunk, Anne Marie, de Boer-Veger, Nienke J., Houwink, Elisa J.F., van Westrhenen, Roos, Wilffert, Bob, Deneer, Vera H.M., Mulder, Hans, Brouwer, Jurriaan M.J.L., Nijenhuis, Marga, Soree, Bianca, Guchelaar, Henk Jan, Swen, Jesse J., van Schaik, Ron H.N., Weide, Jan van der, Rongen, Gerard A.P.J.M., Buunk, Anne Marie, de Boer-Veger, Nienke J., Houwink, Elisa J.F., van Westrhenen, Roos, Wilffert, Bob, Deneer, Vera H.M., and Mulder, Hans

Abstract

The Dutch Pharmacogenetics Working Group (DPWG) guideline presented here, presents the gene-drug interaction between the genes CYP2C19 and CYP2D6 and antidepressants of the selective serotonin reuptake inhibitor type (SSRIs). Both genes’ genotypes are translated into predicted normal metabolizer (NM), intermediate metabolizer (IM), poor metabolizer (PM), or ultra-rapid metabolizer (UM). Evidence-based dose recommendations were obtained, based on a structured analysis of published literature. In CYP2C19 PM patients, escitalopram dose should not exceed 50% of the normal maximum dose. In CYP2C19 IM patients, this is 75% of the normal maximum dose. Escitalopram should be avoided in UM patients. In CYP2C19 PM patients, citalopram dose should not exceed 50% of the normal maximum dose. In CYP2C19 IM patients, this is 70% (65–75%) of the normal maximum dose. In contrast to escitalopram, no action is needed for CYP2C19 UM patients. In CYP2C19 PM patients, sertraline dose should not exceed 37.5% of the normal maximum dose. No action is needed for CYP2C19 IM and UM patients. In CYP2D6 UM patients, paroxetine should be avoided. No action is needed for CYP2D6 PM and IM patients. In addition, no action is needed for the other gene-drug combinations. Clinical effects (increase in adverse events or decrease in efficacy) were lacking for these other gene-drug combinations. DPWG classifies CYP2C19 genotyping before the start of escitalopram, citalopram, and sertraline, and CYP2D6 genotyping before the start of paroxetine as “potentially beneficial” for toxicity/effectivity predictions. This indicates that genotyping prior to treatment can be considered on an individual patient basis.

Published
2022

18. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients

Author

Apotheek Onderzoek, Cancer, Arts Assistenten Longziekten, Longziekten, Infection & Immunity, Researchgr. Systems Radiology, Circulatory Health, Regenerative Medicine and Stem Cells, MS Medische Oncologie, Apotheek O&O&O, Brain, Child Health, MS Hoofd-Hals Chirurgische Oncologie, Apotheek Klinische Farmacie, de Jong, Corine, Chargi, Najiba, Herder, Gerarda J.M., van Haarlem, Simone W.A., van der Meer, Femke, van Lindert, Anne S.R., ten Heuvel, Alexandra, Brouwer, Jan, de Jong, Pim A., Devriese, Lot A., Huitema, Alwin D.R., Egberts, Toine C.G., de Bree, Remco, Deneer, Vera H.M., Apotheek Onderzoek, Cancer, Arts Assistenten Longziekten, Longziekten, Infection & Immunity, Researchgr. Systems Radiology, Circulatory Health, Regenerative Medicine and Stem Cells, MS Medische Oncologie, Apotheek O&O&O, Brain, Child Health, MS Hoofd-Hals Chirurgische Oncologie, Apotheek Klinische Farmacie, de Jong, Corine, Chargi, Najiba, Herder, Gerarda J.M., van Haarlem, Simone W.A., van der Meer, Femke, van Lindert, Anne S.R., ten Heuvel, Alexandra, Brouwer, Jan, de Jong, Pim A., Devriese, Lot A., Huitema, Alwin D.R., Egberts, Toine C.G., de Bree, Remco, and Deneer, Vera H.M.

Published
2022

19. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs

Author

Apotheek Klinische Farmacie, Brouwer, Jurriaan M.J.L., Nijenhuis, Marga, Soree, Bianca, Guchelaar, Henk Jan, Swen, Jesse J., van Schaik, Ron H.N., Weide, Jan van der, Rongen, Gerard A.P.J.M., Buunk, Anne Marie, de Boer-Veger, Nienke J., Houwink, Elisa J.F., van Westrhenen, Roos, Wilffert, Bob, Deneer, Vera H.M., Mulder, Hans, Apotheek Klinische Farmacie, Brouwer, Jurriaan M.J.L., Nijenhuis, Marga, Soree, Bianca, Guchelaar, Henk Jan, Swen, Jesse J., van Schaik, Ron H.N., Weide, Jan van der, Rongen, Gerard A.P.J.M., Buunk, Anne Marie, de Boer-Veger, Nienke J., Houwink, Elisa J.F., van Westrhenen, Roos, Wilffert, Bob, Deneer, Vera H.M., and Mulder, Hans

Published
2022

20. Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

Author

Verpleegafdeling Cardiologie, Team Medisch, Circulatory Health, Apotheek Klinische Farmacie, Claassens, Daniel M.F., van Dorst, Pim W.M., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Postma, Maarten J., Deneer, Vera H.M., ten Berg, Jurriën M., Boersma, Cornelis, Verpleegafdeling Cardiologie, Team Medisch, Circulatory Health, Apotheek Klinische Farmacie, Claassens, Daniel M.F., van Dorst, Pim W.M., Vos, Gerrit J.A., Bergmeijer, Thomas O., Hermanides, Renicus S., van ’t Hof, Arnoud W.J., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Postma, Maarten J., Deneer, Vera H.M., ten Berg, Jurriën M., and Boersma, Cornelis

Published
2022

21. Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial

Author

Verpleegafdeling Cardiologie, Apotheek Klinische Farmacie, Tavenier, Anne H., Claassens, Daniel M.F., Hermanides, Renicus S., Vos, Gerrit J.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., van 't Hof, Arnoud W.J., ten Berg, Jurriën M., Verpleegafdeling Cardiologie, Apotheek Klinische Farmacie, Tavenier, Anne H., Claassens, Daniel M.F., Hermanides, Renicus S., Vos, Gerrit J.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., van 't Hof, Arnoud W.J., and ten Berg, Jurriën M.

Published
2022

22. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)

Author

Apotheek Klinische Farmacie, Matic, Maja, Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A.P.J.M., Weide, Jan van der, Wilffert, Bob, Swen, Jesse J., Guchelaar, Henk Jan, van Schaik, Ron H.N., Deneer, Vera H.M., Apotheek Klinische Farmacie, Matic, Maja, Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A.P.J.M., Weide, Jan van der, Wilffert, Bob, Swen, Jesse J., Guchelaar, Henk Jan, van Schaik, Ron H.N., and Deneer, Vera H.M.

Published
2022

24. The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patients

Author

de Jong, Corine, primary, Chargi, Najiba, additional, Herder, Gerarda J.M., additional, van Haarlem, Simone W.A., additional, van der Meer, Femke, additional, van Lindert, Anne S.R., additional, ten Heuvel, Alexandra, additional, Brouwer, Jan, additional, de Jong, Pim A., additional, Devriese, Lot A., additional, Huitema, Alwin D.R., additional, Egberts, Toine C.G., additional, de Bree, Remco, additional, and Deneer, Vera H.M., additional

Published
2022
Full Text
View/download PDF

25. A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery—Rationale and design of the POPular CABG trial

Author

Willemsen, Laura M., Janssen, Paul W.A., Hackeng, Chris M., Kelder, Johannes C., Tijssen, Jan G.P., van Straten, Albert H.M., Soliman-Hamad, Mohammed A., Deneer, Vera H.M., Daeter, Edgar J., Sonker, Uday, Klein, Patrick, ten Berg, Jurriën M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Cardiology, and ACS - Heart failure & arrhythmias

Subjects
Ticagrelor, medicine.medical_specialty, Computed Tomography Angiography, medicine.medical_treatment, Myocardial Infarction, 030204 cardiovascular system & hematology, Coronary Angiography, Revascularization, Sudden death, Placebos, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Multicenter trial, Occlusion, medicine, Humans, Saphenous Vein, 030212 general & internal medicine, Myocardial infarction, Platelet activation, Coronary Artery Bypass, Vascular Patency, Aged, Computed tomography angiography, Aspirin, medicine.diagnostic_test, business.industry, Graft Occlusion, Vascular, medicine.disease, Surgery, Death, Sudden, Cardiac, surgical procedures, operative, Research Design, Sample Size, Drug Therapy, Combination, Cardiology and Cardiovascular Medicine, business, Platelet Aggregation Inhibitors, medicine.drug
Abstract

Rationale An estimated 15% of saphenous vein grafts (SVGs) occlude in the first year after coronary artery bypass grafting (CABG) despite aspirin therapy. Graft occlusion can result in symptoms, myocardial infarction, and death. SVG occlusion is primarily caused by atherothrombosis, in which platelet activation plays a pivotal role. Evidence regarding the effect of stronger platelet inhibition on SVG patency after CABG is limited. The main objective of the POPular CABG trial is to determine whether dual antiplatelet therapy with aspirin plus ticagrelor improves SVG patency when compared to aspirin alone. Study The POPular CABG is a randomized, double-blind, placebo-controlled, multicenter trial investigating the effect of adding ticagrelor to standard aspirin therapy on the rate of SVG occlusion. A total of 500 patients undergoing CABG with ≥ 1 SVG are randomized to ticagrelor or placebo. The primary end point is SVG occlusion rate, assessed with coronary computed tomography angiography at 1 year. Secondary end points are stenoses and occlusions in both SVGs and arterial grafts and SVG failure at 1 year, defined as a composite of SVG occlusion on coronary computed tomography angiography or coronary angiography, SVG revascularization, myocardial infarction in the territory supplied by an SVG, or sudden death. Safety end points are bleeding events at 30 days and 1 year. Conclusion The POPular CABG trial investigates whether adding ticagrelor to standard aspirin after CABG reduces the rate of SVG occlusion at 1 year.

Published
2020

26. Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients

Author

Claassens, Daniel M.F., primary, Gimbel, Marieke E., additional, Bergmeijer, Thomas O., additional, Vos, Gerrit J.A., additional, Hermanides, Renicus S., additional, van der Harst, Pim, additional, Barbato, Emanuele, additional, Morisco, Carmine, additional, Tjon Joe Gin, Richard M., additional, de Vrey, Evelyn A., additional, Heestermans, Ton A.C.M., additional, Jukema, J. Wouter, additional, von Birgelen, Clemens, additional, Waalewijn, Reinier A., additional, Hofma, Sjoerd H., additional, den Hartog, Frank R., additional, Voskuil, Michiel, additional, van't Hof, Arnoud W.J., additional, Asselbergs, Folkert W., additional, Mosterd, A., additional, Herrman, Jean-Paul R., additional, Dewilde, Willem, additional, Mahmoodi, Bakhtawar K., additional, Deneer, Vera H.M., additional, and ten Berg, Jurriën M., additional

Published
2021
Full Text
View/download PDF

27. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines

Author

Abdullah-Koolmees, Heshu, van Keulen, Antonius M., Nijenhuis, Marga, Deneer, Vera H.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
medicine.medical_specialty, Evidence-based practice, Review, CYP2C19, 030226 pharmacology & pharmacy, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, DPWG, Medicine, Pharmacology (medical), guidelines, Intensive care medicine, Genetic testing, pharmacogenetics, Pharmacology, pharmacogenomics, CPIC, medicine.diagnostic_test, Thiopurine methyltransferase, biology, business.industry, CPNDS, lcsh:RM1-950, RNPGx, Irinotecan, lcsh:Therapeutics. Pharmacology, 030220 oncology & carcinogenesis, Pharmacogenomics, recommendations, biology.protein, business, Pharmacogenetics, medicine.drug
Abstract

Many studies have shown that the efficacy and risk of side effects of drug treatment is influenced by genetic variants. Evidence based guidelines are essential for implementing pharmacogenetic knowledge in daily clinical practice to optimize pharmacotherapy of individual patients. A literature search was performed to select committees developing guidelines with recommendations being published in English. The Dutch Pharmacogenetics Working Group (DPWG), the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), and the French National Network (Réseau) of Pharmacogenetics (RNPGx) were selected. Their guidelines were compared with regard to the methodology of development, translation of genotypes to predicted phenotypes, pharmacotherapeutic recommendations and recommendations on genotyping. A detailed overview of all recommendations for gene-drug combinations is given. The committees have similar methodologies of guideline development. However, the objectives differed at the start of their projects, which have led to unique profiles and strengths of their guidelines. DPWG and CPIC have a main focus on pharmacotherapeutic recommendations for a large number of drugs in combination with a patient’s genotype or predicted phenotype. DPWG, CPNDS and RNPGx also recommend on performing genetic testing in daily clinical practice, with RNPGx even describing specific clinical settings or medical conditions for which genotyping is recommended. Discordances exist, however committees also initiated harmonizing projects. The outcome of a consensus project was to rename “extensive metabolizer (EM)” to “normal metabolizer (NM)”. It was decided to translate a CYP2D6 genotype with one nonfunctional allele (activity score 1.0) into the predicted phenotype of intermediate metabolizer (IM). Differences in recommendations are the result of the methodologies used, such as assessment of dose adjustments of tricyclic antidepressants. In some cases, indication or dose specific recommendations are given for example for clopidogrel, codeine, irinotecan. The following drugs have recommendations on genetic testing with the highest level: abacavir (HLA), clopidogrel (CYP2C19), fluoropyrimidines (DPYD), thiopurines (TPMT), irinotecan (UGT1A1), codeine (CYP2D6), and cisplatin (TPMT). The guidelines cover many drugs and genes, genotypes, or predicted phenotypes. Because of this and their unique features, considering the totality of guidelines are of added value. In conclusion, many evidence based pharmacogenetics guidelines with clear recommendations are available for clinical decision making by healthcare professionals, patients and other stakeholders.

Published
2021

28. Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Claassens, Daniel M.F., Gimbel, Marieke E., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., de Vrey, Evelyn A., Heestermans, Ton A.C.M., Jukema, J. Wouter, von Birgelen, Clemens, Waalewijn, Reinier A., Hofma, Sjoerd H., den Hartog, Frank R., Voskuil, Michiel, van't Hof, Arnoud W.J., Asselbergs, Folkert W., Mosterd, A., Herrman, Jean Paul R., Dewilde, Willem, Mahmoodi, Bakhtawar K., Deneer, Vera H.M., ten Berg, Jurriën M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Claassens, Daniel M.F., Gimbel, Marieke E., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., de Vrey, Evelyn A., Heestermans, Ton A.C.M., Jukema, J. Wouter, von Birgelen, Clemens, Waalewijn, Reinier A., Hofma, Sjoerd H., den Hartog, Frank R., Voskuil, Michiel, van't Hof, Arnoud W.J., Asselbergs, Folkert W., Mosterd, A., Herrman, Jean Paul R., Dewilde, Willem, Mahmoodi, Bakhtawar K., Deneer, Vera H.M., and ten Berg, Jurriën M.

Published
2021

30. Clopidogrel Versus Ticagrelor or Prasugrel after Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., Van 'T Hof, Arnoud W.J., Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., Ten Berg, Jurriën M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., Van 'T Hof, Arnoud W.J., Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., and Ten Berg, Jurriën M.

Published
2021

32. Clopidogrel Versus Ticagrelor or Prasugrel after Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

Author

Circulatory Health, Team Medisch, Apotheek Klinische Farmacie, Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., Van 'T Hof, Arnoud W.J., Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., Ten Berg, Jurriën M., Circulatory Health, Team Medisch, Apotheek Klinische Farmacie, Claassens, Daniel M.F., Bergmeijer, Thomas O., Vos, Gerrit J.A., Hermanides, Renicus S., Van 'T Hof, Arnoud W.J., Van Der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M., Asselbergs, Folkert W., Mosterd, Arend, Herrman, Jean Paul R., Dewilde, Willem J.M., Janssen, Paul W.A., Kelder, Johannes C., Mahmoodi, Bakhtawar K., Deneer, Vera H.M., and Ten Berg, Jurriën M.

Published
2021

33. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older—rationale and design of the POPular AGE study

Author

Qaderdan, Khalid, Ishak, Maycel, Heestermans, Antonius A.C.M., de Vrey, Evelyn, Jukema, Wouter J., Voskuil, Michiel, de Boer, Menko-Jan, vanʼt Hof, Arnoud W.J., Groenemeijer, Björn E., Vos, Gerrit-Jan A., Janssen, Paul W.A., Bergmeijer, Thomas O., Kelder, Johannes C., Deneer, Vera H.M., and ten Berg, Jurriën M.

Published
2015
Full Text
View/download PDF

35. Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype

Author

Claassens, Daniel M.F., primary, Bergmeijer, Thomas O., additional, Vos, Gerrit J.A., additional, Hermanides, Renicus S., additional, van ’t Hof, Arnoud W.J., additional, van der Harst, Pim, additional, Barbato, Emanuele, additional, Morisco, Carmine, additional, Tjon Joe Gin, Richard M., additional, Asselbergs, Folkert W., additional, Mosterd, Arend, additional, Herrman, Jean-Paul R., additional, Dewilde, Willem J.M., additional, Janssen, Paul W.A., additional, Kelder, Johannes C., additional, Mahmoodi, Bakhtawar K., additional, Deneer, Vera H.M., additional, and ten Berg, Jurriën M., additional

Published
2021
Full Text
View/download PDF

36. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy

Author

de Jong, Corine, Deneer, Vera H.M., Kelder, Johannes C., Ruven, Henk, Egberts, Toine C.G., Herder, Gerarda J.M., Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
Pulmonary and Respiratory Medicine, Oncology, small cell lung cancer (SCLC), lactate dehydrogenase (LDH), Non-small cell lung cancer (NSCLC), carcinoembryonic antigen (CEA), noninvasive quantification of tumor biomarkers
Abstract

Background: In addition to radiological evaluation, biomarkers may be useful in providing early information on the response to treatment, and supporting clinical decision-making. The objective of this study was to investigate carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH) as biomarkers for early assessment of response in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy. Methods: A retrospective follow-up study was conducted from 2012 to 2017 among 593 consecutive patients with advanced NSCLC treated with first-line platinum-based chemotherapy in a large teaching hospital in the Netherlands. Pretreatment biomarker levels and changes from pretreatment levels were studied for association with radiologic response (partial response [PR] or complete response [CR], according to RECIST 1.1) using multivariate logistic regression, and with overall survival using COX proportional hazard modeling. Patient and disease characteristics such as age and disease stage were taken into account as potential confounding factors. Results: Decreases in CEA and LDH (≥ 20%), particularly early in treatment, were significantly associated with better radiological response. Increases in these biomarkers (≥ 20%) and high pretreatment LDH levels (≥ 247 U/L) were significantly associated with lower overall survival. Conclusions: Our results support determination of CEA and LDH levels for earlier assessment of response to platinum-based chemotherapy in patients with advanced NSCLC. Hence, routine determination and evaluation of CEA and LDH levels, prior to each cycle of platinum-based chemotherapy in advanced NSCLC, should be considered as part of daily clinical practice. Key points: Significant findings of the study: Serum biomarkers in monitoring of treatment in advanced NSCLC would be useful. CEA and LDH decrease (≥ 20%) is favorable for achieving radiological response. High LDH levels and CEA/LDH increase (≥ 20%) is associated with reduced survival. What this study adds: Monitoring of CEA seems to be particularly relevant in early stage of treatment. CEA and LDH determination should be considered as part of daily clinical practice.

Published
2020

37. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines

Author

Lunenburg, Carin A.T.C., van der Wouden, Cathelijne H., Nijenhuis, Marga, Crommentuijn-van Rhenen, Mandy H., de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A., van Schaik, Ron H.N., van der Weide, Jan, Wilffert, Bob, Deneer, Vera H.M., Swen, Jesse J., Guchelaar, Henk Jan, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Clinical Chemistry, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Reproductive Origins of Adult Health and Disease (ROAHD), PharmacoTherapy, -Epidemiology and -Economics, and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)

Subjects
Oncology, Antimetabolites, Antineoplastic, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Pharmacogenomic Variants, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Tegafur, Article, Capecitabine, Prognostic markers, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, All institutes and research themes of the Radboud University Medical Center, Drug Therapy, Internal medicine, Dihydropyrimidine dehydrogenase, medicine, Mucositis, Genetics, Humans, Chemotherapy, Genetics(clinical), Genetic Testing, Dihydrouracil Dehydrogenase (NADP), Genetics (clinical), 030304 developmental biology, 0303 health sciences, business.industry, Guideline, medicine.disease, 3. Good health, Haplotypes, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, DPYD, Fluorouracil, business, Pharmacogenetics, medicine.drug
Abstract

Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the starting dose optimization of three anti-cancer drugs (fluoropyrimidines: 5-fluorouracil, capecitabine and tegafur) to decrease the risk of severe, potentially fatal, toxicity (such as diarrhoea, hand-foot syndrome, mucositis or myelosuppression). Dihydropyrimidine dehydrogenase (DPD, encoded by theDPYDgene) enzyme deficiency increases risk of fluoropyrimidine-induced toxicity. TheDPYD-gene activity score, determined by fourDPYDvariants, predicts DPD activity and can be used to optimize an individual’s starting dose. The gene activity score ranges from 0 (no DPD activity) to 2 (normal DPD activity). In case it is not possible to calculate the gene activity score based onDPYDgenotype, we recommend to determine the DPD activity and adjust the initial dose based on available data. For patients initiating 5-fluorouracil or capecitabine: subjects with a gene activity score of 0 are recommended to avoid systemic and cutaneous 5-fluorouracil or capecitabine; subjects with a gene activity score of 1 or 1.5 are recommended to initiate therapy with 50% the standard dose of 5-fluorouracil or capecitabine. For subjects initiating tegafur: subjects with a gene activity score of 0, 1 or 1.5 are recommended to avoid tegafur. Subjects with a gene activity score of 2 (reference) should receive a standard dose. Based on the DPWG clinical implication score,DPYDgenotyping is considered “essential”, therefore directingDPYDtesting prior to initiating fluoropyrimidines.

Published
2020

38. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Jong, Corine, Deneer, Vera H.M., Kelder, Johannes C., Ruven, Henk, Egberts, Toine C.G., Herder, Gerarda J.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Jong, Corine, Deneer, Vera H.M., Kelder, Johannes C., Ruven, Henk, Egberts, Toine C.G., and Herder, Gerarda J.M.

Published
2020

39. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines

Author

Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Lunenburg, Carin A.T.C., van der Wouden, Cathelijne H., Nijenhuis, Marga, Crommentuijn-van Rhenen, Mandy H., de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A., van Schaik, Ron H.N., van der Weide, Jan, Wilffert, Bob, Deneer, Vera H.M., Swen, Jesse J., Guchelaar, Henk Jan, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Lunenburg, Carin A.T.C., van der Wouden, Cathelijne H., Nijenhuis, Marga, Crommentuijn-van Rhenen, Mandy H., de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A., van Schaik, Ron H.N., van der Weide, Jan, Wilffert, Bob, Deneer, Vera H.M., Swen, Jesse J., and Guchelaar, Henk Jan

Published
2020

40. A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery—Rationale and design of the POPular CABG trial

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Willemsen, Laura M., Janssen, Paul W.A., Hackeng, Chris M., Kelder, Johannes C., Tijssen, Jan G.P., van Straten, Albert H.M., Soliman-Hamad, Mohammed A., Deneer, Vera H.M., Daeter, Edgar J., Sonker, Uday, Klein, Patrick, ten Berg, Jurriën M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Willemsen, Laura M., Janssen, Paul W.A., Hackeng, Chris M., Kelder, Johannes C., Tijssen, Jan G.P., van Straten, Albert H.M., Soliman-Hamad, Mohammed A., Deneer, Vera H.M., Daeter, Edgar J., Sonker, Uday, Klein, Patrick, and ten Berg, Jurriën M.

Published
2020

42. Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial

Author

Global Health, Researchgr. Cardiovasculaire Radiologie, Circulatory Health, Team Medisch, Apotheek Klinische Farmacie, Willemsen, Laura M., Janssen, Paul W.A., Peper, Joyce, Soliman-Hamad, Mohamed A., van Straten, Albert H.M., Klein, Patrick, Hackeng, Chris M., Sonker, Uday, Bekker, Margreet W.A., von Birgelen, Clemens, Brouwer, Marc A., van der Harst, Pim, Vlot, Eline A., Deneer, Vera H.M., Chan Pin Yin, Dean R.P.P., Gimbel, Marieke E., Beukema, Kasper F., Daeter, Edgar J., Kelder, Johannes C., Tijssen, Jan G.P., Rensing, Benno J.W.M., van Es, Hendrik W., Swaans, Martin J., Ten Berg, Jurrien M., Global Health, Researchgr. Cardiovasculaire Radiologie, Circulatory Health, Team Medisch, Apotheek Klinische Farmacie, Willemsen, Laura M., Janssen, Paul W.A., Peper, Joyce, Soliman-Hamad, Mohamed A., van Straten, Albert H.M., Klein, Patrick, Hackeng, Chris M., Sonker, Uday, Bekker, Margreet W.A., von Birgelen, Clemens, Brouwer, Marc A., van der Harst, Pim, Vlot, Eline A., Deneer, Vera H.M., Chan Pin Yin, Dean R.P.P., Gimbel, Marieke E., Beukema, Kasper F., Daeter, Edgar J., Kelder, Johannes C., Tijssen, Jan G.P., Rensing, Benno J.W.M., van Es, Hendrik W., Swaans, Martin J., and Ten Berg, Jurrien M.

Published
2020

43. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines

Author

Apotheek Klinische Farmacie, Lunenburg, Carin A.T.C., van der Wouden, Cathelijne H., Nijenhuis, Marga, Crommentuijn-van Rhenen, Mandy H., de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A., van Schaik, Ron H.N., van der Weide, Jan, Wilffert, Bob, Deneer, Vera H.M., Swen, Jesse J., Guchelaar, Henk Jan, Apotheek Klinische Farmacie, Lunenburg, Carin A.T.C., van der Wouden, Cathelijne H., Nijenhuis, Marga, Crommentuijn-van Rhenen, Mandy H., de Boer-Veger, Nienke J., Buunk, Anne Marie, Houwink, Elisa J.F., Mulder, Hans, Rongen, Gerard A., van Schaik, Ron H.N., van der Weide, Jan, Wilffert, Bob, Deneer, Vera H.M., Swen, Jesse J., and Guchelaar, Henk Jan

Published
2020

49. CLOPIDOGREL VERSUS TICAGRELOR AND PRASUGREL IN PRIMARY PERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH A NORMAL FUNCTION CYP2C19 GENE: A SUB-STUDY FROM THE POPULAR GENETICS

Author

Claassens, Daniel, primary, Bergmeijer, Thomas, additional, Vos, Gerrit J.A., additional, Hermanides, Rik S., additional, Hof, Arnoud, additional, van der Harst, Pim, additional, Barbato, Emanuele, additional, Morisco, Carmine, additional, Gin, Richard M. Tjon Joe, additional, Asselbergs, Folkert, additional, Mosterd, Arend, additional, Herrman, Jean-Paul, additional, Dewilde, Willem J.M., additional, Deneer, Vera H.M., additional, and Berg, Jurrien M. Ten, additional

Published
2020
Full Text
View/download PDF

50. CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

Author

Bergmeijer, Thomas O., Janssen, Paul W.A., Schipper, Jurjan C., Qaderdan, Khalid, Ishak, Maycel, Ruitenbeek, Rianne S., Asselbergs, Folkert W., van ‘t Hof, Arnoud W.J., Dewilde, Willem J.M., Spanó, Fabrizio, Herrman, Jean-Paul R., Kelder, Johannes C., Postma, Maarten J., de Boer, Anthonius, Deneer, Vera H.M., and ten Berg, Jurriën M.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results